Drug Database
PA

pancrelipase (Ultrase MT20 / Ultrase MT / Ultresa)

✓ Approved

Adare Pharma Solutions · PNLIP

What is pancrelipase?

pancrelipase is a therapeutic agent developed by Adare Pharma Solutions. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesUltrase MT20, Ultrase MT, Ultresa
CompanyAdare Pharma Solutions
Molecular TargetPNLIP
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Adare Pharma Solutions

Mechanism of Action

Molecular Targets

pancrelipase acts on 1 molecular target:

PNLIPpancreatic lipase (PL, PNLIPD)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pancrelipase is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
InvestigationsFaecal fat increased✓ Approved
Gastrointestinal disordersSteatorrhoea✓ Approved
Gastrointestinal disordersPancreatic failure✓ Approved

Related Research Articles

PubMedBioanalysis2026-05-24

European bioanalysis forum recommendations for strengthening bioanalytical method transfer and validation through collaborative interactions.

Andersen Lene L, Gaertner Fabian F, Ahmedova Sibel S, Edwards Sharareh S et al.

Bioanalytical method transfer is a critical and often vulnerable step in drug development, yet many challenges arise not from technical limitations but from misalignment, communication gaps and loss of scientific context as work moves between organizations. The European Bioanalysis Forum conducted a multi-table Pharma/CRO workshop and community survey to identify the behaviors that most influence transfer success. The discussions revealed consistent themes: early SME engagement, shared understanding of scientific intent, proactive communication, joint risk management and a clear responsibility split. This paper summarizes these insights and provides practical, interaction-focused recommendations to strengthen collaboration across method development, transfer and validation. Rather than prescribing templates or checklists, the European Bioanalysis Forum outlines behaviors and principles that promote clarity, predictability and scientific convergence. Reliable method transfer emerges from partnership mind-set and deliberate interaction, not procedural formality.

PMID 42177673
Read full article →
PubMedCell reports2026-05-24

CLIC-dependent internalization of caveolin-1 to lysosomal vacuoles in response to osmotic regulation.

Wong Timothy H TH, Lima Matheus F MF, Nagrath Aditya A, Li Y Lydia YL et al.

Originally thought to be a major endocytic portal, caveolae function as a membrane buffer, whereby caveolae flattening protects the plasma membrane from rupture under mechanical stress, such as hypotonic shock. However, the fate of the caveolae coat protein caveolin-1 upon caveolae flattening is not known. Here, extended hypotonic shock induces ubiquitin-independent, CLIC-dependent endocytosis of caveolin-1 to large, intracellular, CD44-positive, pH-neutral lysosomal vacuoles negative for multivesicular body markers. Caveolin-1 recycles from these vacuoles to the plasma membrane upon return to isotonic conditions. Caveolin-1 internalization occurs upon reduced cell volume due to extended hypotonic shock as well as in low-tension cells grown on reduced-stiffness hydrogels. Upon hypertonic shock, caveolin-1 internalization occurs in PC3 cells, lacking cavin-1 and caveolae, and is inhibited upon cavin-1 reintroduction. CLIC endocytosis of non-caveolar caveolin-1 to neutral pH lysosomal vacuoles identifies a non-caveolar endocytic and recycling pathway for caveolin-1 in response to reduced membrane tension.

PMID 42176267
Read full article →
PubMedCell death & disease2026-05-24

USAG-1 aggravates renal ischemia‒reperfusion injury via promoting GPX4 degradation-induced ferroptosis.

Li Xiaohu X, Wang Huimeng H, Ma Hongxuan H, Sun Jiajia J et al.

Renal ischemia‒reperfusion injury (IRI) remains an inevitable complication in kidney transplantation and a leading cause of delayed graft function (DGF). Ferroptosis, a form of iron-dependent lipid peroxidation-driven cell death, has emerged as an important mechanism contributing to renal IRI. Although uterine sensitization-associated gene-1 (USAG-1) has been implicated in both acute and chronic kidney injury, its involvement in IRI-associated ferroptosis has not been elucidated. In this study, using murine renal ischemia-reperfusion models and human transplant kidney biopsies (from donation after circulatory death donors), we demonstrate that USAG-1 is significantly upregulated under ischemic stress. Importantly, higher USAG-1 expression in donor kidneys was associated with worse allograft function post-transplantation, suggesting that USAG-1 may serve as a promising biomarker for transplant injury and outcomes. In addition, genetic ablation of USAG-1 markedly attenuated both IRI- and folic acid-induced ferroptosis, accompanied by reduced acute kidney injury severity. Mechanistically, glutathione peroxidase 4 (GPX4) was a critical downstream effector of USAG-1 in mediating ferroptotic processes. HSP family A member 5 (HSPA5), a canonical molecular chaperone, stabilized GPX4 via direct interactions. Our findings revealed that overexpressed USAG-1 competitively binds to HSPA5, thereby disrupting the HSPA5-GPX4 interaction. This interference was abrogated by truncation mutants of USAG-1 that failed to interact with HSPA5. Notably, functional validation of the USAG-1/HSPA5/GPX4 axis confirmed that preserving HSPA5-GPX4 binding mitigated ferroptosis and alleviated renal injury. Overall, our study reveals a previously unrecognized mechanism by which USAG-1 promotes ferroptosis in renal IRI and highlights the therapeutic potential of targeting the USAG-1/HSPA5/GPX4 axis to improve graft outcomes post-transplantation.

PMID 42177164
Read full article →
PubMedThe Journal of clinical endocrinology and metabolism2026-05-24

IGF-1 and recovery in anorexia nervosa: evidence from population-based and clinical cohorts.

Dani Cristiano C, Tarchi Livio L, Bonacchi Lorenzo L, Haydar Sara S et al.

Anorexia nervosa (AN) is associated with severe metabolic and endocrine alterations, including growth hormone (GH) resistance and reduced insulin-like growth factor 1 (IGF-1). The longitudinal behavior of IGF-1 during treatment remains incompletely characterized. To evaluate IGF-1 levels in current and weight restored AN, determine metabolic correlates, and examine longitudinal changes during clinical treatment. Cross-sectional analysis in a population-based cohort and longitudinal analysis in a clinical cohort. UK Biobank (UKB) and a specialist eating disorder clinic. (i) UKB: 129 adult women with current AN, 2,380 weight restored AN, and 2,380 healthy controls (HC) matched for age, sex, and BMI. (ii) Clinical cohort: 189 adult women with AN assessed at baseline and 12-month follow-up. Plasma IGF-1 levels; secondary metabolic and reproductive hormones including GH, insulin, glucose, FT3, and gonadal hormones. Across the UKB groups, IGF-1 levels showed a graded pattern: lowest in current AN, medium in weight restored AN, and highest in HC. In the clinical cohort, IGF-1 correlated positively with insulin, glucose, and FT3, and negatively with GH, consistent with GH resistance. IGF-1 levels increased significantly over 12 months of treatment (p = 0.003), with higher BMI at baseline predicting greater increases. Higher IGF-1 levels were associated with greater likelihood of menstrual function independent of BMI (p < 0.001). IGF-1 appears reduced in current AN and may only partly normalize with weight restoration. IGF-1 may reflect metabolic state and reproductive function, suggesting value as an indicator of severity and treatment response.

PMID 42177039
Read full article →
PubMedJournal of the European Academy of Dermatology and Venereology : JEADV2026-05-24

Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.

Warren Richard B RB, Gooderham Melinda M, Lain Edward E, Bissonnette Robert R et al.

High-impact site plaque psoriasis is difficult to treat. Icotrokinra, an oral peptide with high specificity for the interleukin (IL)-23 receptor, demonstrated significantly higher rates of high-impact site psoriasis clearance, versus placebo, with no safety signals, through Week (W)16. Report clinical response rates and safety through 1 year of icotrokinra treatment in participants with high-impact site plaque psoriasis. Participants (≥12 years of age; psoriasis body surface area ≥1%; Investigator's Global Assessment [IGA] ≥2) with at least moderate scalp, genital or hand/foot psoriasis were randomized (2:1) to once-daily icotrokinra 200 mg (N = 208) or placebo (N = 103), with placebo-to-icotrokinra transition at W16 (N = 92). Rates (using nonresponder imputation) of achieving clear/almost clear (0/1) or clear (0) overall skin (IGA), genital (static Physician's Global Assessment of genitalia [sPGA-G]), hand/foot (hf-PGA) psoriasis and absent/very mild (0/1) or absent (0) scalp psoriasis (scalp-specific-IGA [ss-IGA]), modified Nail Psoriasis Severity Index (mNAPSI) percent improvement and safety were assessed through W52. Eighty-eight per cent (275/311) of participants completed treatment through W52. In icotrokinra-randomized participants, response rates increased through W24 and were durable through W52 for overall psoriasis clearance (IGA 0/1 range: 67%-70%) and across high-impact sites (ss-IGA 0/1: 72%-78%; sPGA-G 0/1: 85%-90%; hf-PGA 0/1: 54%-62%); responses were consistent among placebo-randomized participants after transitioning to icotrokinra. High proportions of icotrokinra-randomized participants achieved complete clearance during W24-52 (IGA 0: 44%-51%; ss-IGA 0: 57%-66%; sPGA-G 0: 73%-84%; hf-PGA 0: 44%-58%). Mean mNAPSI improvement increased from W16 (33%) to W52 (62%). Exposure-adjusted rates of participants with ≥1 adverse event (AE) or serious AE through W16 were similar between icotrokinra and placebo, with no increase in AE rates or occurrence of a safety signal through W52. Icotrokinra demonstrated high and durable rates of psoriasis clearance across high-impact sites, with a favourable safety profile, through 1 year.

PMID 42175814
Read full article →
PubMedJournal of aerosol medicine and pulmonary drug delivery2026-05-24

Formulation and Development of Spray-Dried Atorvastatin Nanoparticles for Potential Antifungal Applications.

Alkathiri Fai F, Altuwaijr Njoud N, Alfaraj Rihaf R, Fitaihi Rawan R et al.

Atorvastatin (ATR), traditionally prescribed as an antihyperlipidemic agent, has shown promising therapeutic potential beyond its primary indication, including anti-inflammatory, antioxidant, and antifungal properties. However, its clinical application is limited by poor solubility and low bioavailability. To address these limitations, ATR-loaded nanoparticles were prepared using Gelucire® 44/14 and Gelucire 50/13 at ratios of 1:1 and 1:3 through spray-drying. The formulations were evaluated for particle size, zeta potential, encapsulation efficiency, solubility, morphology, dissolution, and antifungal activity against four fungal strains of clinical relevance. Increasing the Gelucire ratio from 1:1 to 1:3 significantly reduced particle size (227.30 ± 4.1 to 150.71 ± 3.8 nm) and improved encapsulation efficiency, reaching 83.53%. Dissolution was markedly enhanced, with ATR-GR 44/14 (1:3) achieving nearly complete release within 5 hours. Morphological analysis confirmed the formation of uniformly dispersed nanoparticles. Importantly, antifungal assays demonstrated that ATR-GR 44/14 (1:3) exhibited superior activity against multiple fungal strains compared with other formulations and pure ATR. Spray-dried ATR-GR nanoparticles offer an effective strategy to overcome solubility barriers while enhancing antifungal efficacy. These findings support their potential as a repurposed therapeutic platform for fungal infections and justify further preclinical and clinical investigation, including future exploration of these spray-dried systems as candidates for inhaled antifungal delivery.

PMID 42176256
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about pancrelipase